HYPLUS TECHNOLOGIES PTE. LTD.
UEN: 200514833G
HYPLUS TECHNOLOGIES PTE. LTD.(200514833G) is a Singapore business with registered business address at 5 ANG MO KIO INDUSTRIAL PARK 2A, 3-12, AMK TECH II, Singapore 567760. They specialise in the area of MANUFACTURE OF OTHER ELECTRONIC COMPONENTS AND BOARDS N.E.C. and WHOLESALE OF ELECTRONIC COMPONENTS.
| Company Name | HYPLUS TECHNOLOGIES PTE. LTD. |
| Unique Entity Number | 200514833G |
| Entity Type | Local Company |
| Entity Status | Live Company |
| Incorporate Day | 24 October 2005 |
| Address |
5 ANG MO KIO INDUSTRIAL PARK 2A #3-12 AMK TECH II Singapore 567760 |
| Products / Services |
MANUFACTURE OF OTHER ELECTRONIC COMPONENTS AND BOARDS N.E.C. WHOLESALE OF ELECTRONIC COMPONENTS |
| Number of Officers | 2 |
| Paid Up Capital | SGD 20000 |
Breaking! Business News
Bombardier Releases its 2019 Activity Report, Highlighting Sustainability Milestones and ObjectivesBombardier Releases its 2019 Activity Report, Highlighting Sustainability Milestones and ObjectivesG...
Read More
International Spirits & Wellness Holdings Enters Joint-Venture Agreement with Official Distributor of Top-Selling Crypto Mining EquipmentInternational Spirits & Wellness Holdings Enters Joint-Venture Agreement with Official Distributor o...
Read More
Zoom Hires Damien Hooper-Campbell as Chief Diversity OfficerZoom Hires Damien Hooper-Campbell as Chief Diversity OfficerTech Industry Veteran to Lead Expansion ...
Read More
Wasabi Builds on Explosive Growth with $30 Million Funding RoundWasabi Builds on Explosive Growth with $30 Million Funding RoundNew investment to drive Wasabi’s g...
Read More
Virtusa to Increase Speed, Reduce Costs of Critical Digital Transformation InitiativesVirtusa to Increase Speed, Reduce Costs of Critical Digital Transformation InitiativesNew Digital Tr...
Read More
Philips Foundation publishes its 2019 Annual Report Philips Foundation publishes its 2019 Annual Report GlobeNewswireMay 28, 2020May 28, 2020 ...
Read More
Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II StudyAtriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II StudyGlob...
Read More
Capgemini Press Release // Capgemini and Audi launch new Joint Venture: XL2Capgemini Press Release // Capgemini and Audi launch new Joint Venture: XL2GlobeNewswireMay 28, 2020...
Read More